Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma

Respiratory Medicine

Volumn 96, Issue 5, 2002, Pages 322-329

  Yurdakul, A S ^a   Caliir H C ^a   Tunctan B ^b   O G M ^a  

^a Ataturk Chest Disease and Thoracic Surgery Education and Research Hospital Ankara   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Asthma; Formoterol; Theophylline; Treatment; Zafirlukast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; TERBUTALINE; THEOPHYLLINE; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; SCORING SYSTEM; SUSTAINED RELEASE PREPARATION; SYMPTOM; TREATMENT OUTCOME;

EID: 0036587055     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1282     Document Type: Article

References (39)

1. National Institutes of Health. National Heart, Lung, and Blood Institute. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report March 1993. NIH Publication 1995, No. 95-3659.
2. Barnes NC. The place of anti-leukotriene therapy in asthma management guidelines. Eur Respir J 1998; 8: 382-386.
3. National Heart, Lung, and Blood Institute. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 1997. Publication no. 97-4051.
4. Sampson A, Holgate S. Leukotriene modifiers in the treatment of asthma. Br Med J 1998; 316: 1257-1258.
5. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis 1987; 136: 225-244.
6. Christopher JD, Karen LG. Zafirlukast: An update of its pharmacology and therapeutic efficacy in asthma. Drugs 2001; 61(2): 285-315.
7. Sears MR: Use of peak expiratory flow meters in adults: practical aspects. Eur Respir J 1997; 10, Suppl 24: 72S-74S.
8. Quackenboss JJ, Lebowitz MD, Krzyzanowski M. The normal range of diurnal changes in peak expiratory flow rates. Am Rev Respir Dis 1991; 143: 323-330.
9. Molimard M, Bourcereau J, Gros VL, Bourdeix I, Leynadier F, Duroux P. Comparison between formoterol 12 μg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respir Med 2001; 95: 64-70.
10. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RIF. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996; 153: 1739-1748.
11. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Richard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103:1075-1080.
12. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
13. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
14. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997 Nov 13; 337: 1405-1411.
15. Maesen FPV, Smeets JJ, Gubbelmans HLL, Zweers PGMA. Bronchodilator effect of inhaled formoterol vs. salbutamol over 12 hours. Chest 1990; 97: 590-594.
16. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the broncho-protective effect of salmeterol. Chest 1996; 109: 953-956.
17. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-1239.
18. O'Connor BJ, Aikman SL; Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma. N Engl J Med 1992; 327: 1204-1208.
19. Arvidsson P, Larsson S, Loefdahl CG, Melander B, Svedmyr N, Wahlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168-1173.
20. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152: 1170-1174.
21. Spector S, Fish JE. A new approach: clinical review of zafirlukast (Accolate™,ICI-204,219). Eur Respir Rev 1997, 7: 269-273.
22. Finnerty J, Wood-Baker R, Thompson H, et al. Role of leukotrienes in exercise induced asthma. Am Rev Respir Dis 1992; 145: 746-749.
23. Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998; 157: 1363-1371.
24. 4) induced airway inflammation in asthma. Am J respir Crit Care Med 1999 Mar; 159 Suppl. (Pt 2):A642.
25. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152: 897-905.
26. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high dose of inhaled corticosteroids. The Tokyo Joshi Idal Asthma Research Group. Am J Respir Crit Care Med 1997, 155: 1235-1240.
27. Wenzel S, Chervinsky P, Kerwin E, et al. Oral pranlukast (Ultair™) versus inhaled beclomethasone: results of a 12-week trial in patients asthma (abst). Am J Respir Crit Care Med 1997, 155: 203.
28. Nayak AS, Anderson P, Carous BL, et al. Equivalance of adding zafirlukast versus double-dose inhaled corticosteroids in asthmatic patients symptomatic on low dose inhaled corticosteroids (abst). J Allergy Clin Immunol 1998; 101: 233.
29. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for semptomatic mild-to-moderate asthma: A 13 week multicenter study. Clinical Theurapeutics 1997; 19: 675-689.
30. Sussa S, Denns R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist Zafirlukast for mild-to-moderate asthma. Ann Intern Med 1997; 126: 177-183.
31. Kemp JR. Antileukotriene drugs as oral controller therapy for asthma. Eur Respir Rev 1998; 8: 190-193.
32. Magnussen H, Relss G, Jorres R. Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics. Am Rev Respir Dis 1987; 136: 1163-1167.
33. Page CP. Theophylline as an anti-inflammatory agent. Eur Respir Rev 1996; 6: 74-78.
34. Pauwels RA. New aspects of the therapeutic potential of theophylline in asthma. J Allergy Clin Immunol 1989; 83: 548-553.
35. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma: demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151: 1907-1914.
36. Hatzelmann A, Tenor H, Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 1995; 114: 821-831.
37. Pauwels RA, Renterghem DV, Straeten MVD, Johannesson N, Persson CGA. The effece of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol 1985; 76: 583-590.
38. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412-1418.
39. Rivington RN, Boulet L-P, Coté J, Kreisman H, Small DI, Alexander M, Day A, Harsanyi Z, Darke AC. Efficacy of Uniphyl®, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995; 151: 325-332.